MAHA’s next FDA move will block fluoride prescriptions for kids as health risk evidence mounts
The Food and Drug Administration (FDA) made a significant announcement on Tuesday regarding the removal of ingestible fluoride prescription drug products for children from the market. This decision is part of the agency’s effort to eliminate outdated practices related to children’s health and ensure the safety of America’s youth.
According to Department of Health and Human Services spokesman Andrew Nixon, the FDA and HHS are taking bold action to protect children by initiating the removal of unapproved fluoride prescription drug products from the market. These products, which are given to infants and toddlers, have never been approved by the FDA and pose serious risks to developing children. These risks include harm to the gut microbiome, potential thyroid dysfunction, weight gain, and even reduced IQ. Nixon emphasized that this issue is not just a public health concern but also a moral issue.
The FDA has begun the process of removing concentrated ingestible fluoride prescription drug products for children from the market. Ingestible fluoride, such as tablets prescribed to children at high risk for cavities, has been shown to alter the gut microbiome and may be associated with thyroid disorders, weight gain, and decreased IQ. It is important to note that ingestible fluoride is different from other fluoride products, such as toothpaste containing fluoride.
Health and Human Services Secretary Robert F. Kennedy Jr. expressed his support for ending the use of ingestible fluoride, stating that it is long overdue. He highlighted the importance of prioritizing children’s health and development by eliminating these potentially harmful products from the market.
FDA Commissioner Marty Makary emphasized that preventing cavities in children should focus on avoiding excessive sugar intake and maintaining good dental hygiene, rather than altering the child’s microbiome. He noted that fluoride may kill bacteria on teeth but could also harm intestinal bacteria essential for a child’s health.
The FDA is conducting a full safety review, with input from the public, to finalize the details of the plan by October 31. The agency aims to promote safe and effective dental hygiene practices without compromising gut health. Kennedy commended Commissioner Makary for his leadership on this critical issue, stating that the decision brings us closer to fulfilling President Trump’s promise to Make America Healthy Again.
In conclusion, the FDA’s decision to remove ingestible fluoride prescription drug products for children from the market underscores the agency’s commitment to protecting the health and well-being of America’s youth. This action represents a significant step toward ending outdated practices and ensuring the safety of children’s health.
